-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Iovance Biotherapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2023 to Q3 2024.
- Iovance Biotherapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $55.8M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)